Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa InfectionsPRNewsWire • 10/15/20
Armata Pharmaceuticals to Present at the Virtual 2020 World Antimicrobial Resistance CongressPRNewsWire • 09/29/20
Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate UpdatePRNewsWire • 08/13/20